The DOI matches its Crossref record; 127 of the 127 references it cites were found in a registry or an index.
To kill a tumor cell: the potential of proapoptotic receptor agonists
Open accessAbstract
Disturbances in mechanisms that direct abnormal cells to undergo apoptosis frequently and critically contribute to tumorigenesis, yielding a logical target for potential therapeutic intervention.There is currently heightened interest in the extrinsic apoptosis pathway, with several proapoptotic receptor agonists (PARAs) in development.The PARAs include the ligand recombinant human Apo2L/TRAIL and agonistic mAbs.Mechanistic and preclinical data with Apo2L/TRAIL indicate exciting opportunities for synergy with conventional therapies and for combining PARAs with other molecularly targeted agents.Novel molecular biomarkers may help identify those patients most likely to benefit from PARA therapy.Nonstandard abbreviations used: Apaf-1, apoptotic protease-activating factor 1; Apo2L/TRAIL, Apo2 ligand/TNF-related apoptosis-inducing ligand; BH3, Bcl-2 homology 3; CRC, colorectal cancer; DISC, death-inducing signaling complex; DLT, dose-limiting toxicity; IAP, inhibitor of apoptosis; MTD, maximum tolerated dose; NHL, non-Hodgkin lymphoma; NSCLC, non-small cell lung cancer; PARA, proapoptotic receptor agonist; PR, partial response; rhApo2L/TRAIL, recombinant human Apo2L/TRAIL; SAE, serious adverse event; SD, stable disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Thornberry, N. A., & Lazebnik, Y. (1998) · Science · doi:10.1126/science.281.5381.1312 · Cited by 6,887
Nagata, S. (1997) · Cell · doi:10.1016/s0092-8674(00)81874-7 · Cited by 4,938
Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the Fas Pathway of Apoptosis
Li, H., Zhu, H., Xu, C.-J., & Yuan, J. (1998) · Cell · doi:10.1016/s0092-8674(00)81590-1 · Cited by 4,445
Luo, X., Budihardjo, I., Zou, H., Slaughter, C., & Wang, X. (1998) · Cell · doi:10.1016/s0092-8674(00)81589-5 · Cited by 3,626
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416
Live or let die: the cell's response to p53
Vousden, K. H., & Lu, X. (2002) · Nature Reviews Cancer · doi:10.1038/nrc864 · Cited by 3,192
Two CD95 (APO‐1/Fas) signaling pathways
Scaffidi, C., Fulda, S., Srinivasan, A., Friesen, C., Li, F., Tomaselli, K. J., Debatin, K., Krammer, P. H., & Peter, M. E. (1998) · The EMBO Journal · doi:10.1093/emboj/17.6.1675 · Cited by 3,000
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al. (1999) · Nature Medicine · doi:10.1038/5517 · Cited by 2,497
Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy
Fulda, S., & Debatin, K.-M. (2006) · Oncogene · doi:10.1038/sj.onc.1209608 · Cited by 2,312
Safety and antitumor activity of recombinant soluble Apo2 ligand
Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6926 · Cited by 2,213
Self-citationDeath and anti-death: tumour resistance to apoptosis
Igney, F. H., & Krammer, P. H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc776 · Cited by 2,075
Targeting death and decoy receptors of the tumour-necrosis factor superfamily
Ashkenazi, A. (2002) · Nature Reviews Cancer · doi:10.1038/nrc821 · Cited by 1,360
Self-citationTargeting Apoptosis Pathways in Cancer Therapy
Ghobrial, I. M., Witzig, T. E., & Adjei, A. A. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.3.178 · Cited by 1,330
Lowe, S. W., Cepero, E., & Evan, G. (2004) · Nature · doi:10.1038/nature03098 · Cited by 1,309
Apoptosis Initiated When BH3 Ligands Engage Multiple Bcl-2 Homologs, Not Bax or Bak
Willis, S. N., Fletcher, J. I., Kaufmann, T., van Delft, M. F., Chen, L., Czabotar, P. E., Ierino, H., Lee, E. F., Fairlie, W. D., Bouillet, P., et al. (2007) · Science · doi:10.1126/science.1133289 · Cited by 1,125
Promoting apoptosis as a strategy for cancer drug discovery
Fesik, S. W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1736 · Cited by 1,098
KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor gene
Wu, G. S., Burns, T. F., McDonald, E. R., Jiang, W., Meng, R., Krantz, I. D., Kao, G., Gan, D.-D., Zhou, J.-Y., Muschel, R., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-141 · Cited by 1,083
Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2
Strasser, A., Harris, A. W., Bath, M. L., & Cory, S. (1990) · Nature · doi:10.1038/348331a0 · Cited by 905
Cell Death Independent of Caspases: A Review
Bröker, L. E., Kruyt, F. A. E., & Giaccone, G. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2223 · Cited by 898
Database of p53 gene somatic mutations in human tumors and cell lines.
Hollstein, M. C., Rice, K., Greenblatt, M. S., Soussi, T., Fuchs, R., Sørlie, T., Hovig, E. J., Smith‐Sørensen, B., Montesano, R., & Harris, C. C. (1994) · Europe PMC (PubMed Central) · Cited by 858
Apo2L/TRAIL and its death and decoy receptors
LeBlanc, H. N., & Ashkenazi, A. (2003) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401187 · Cited by 854
Self-citationThe machinery of programmed cell death
Zimmermann, K. C., Bonzon, C., & Green, D. R. (2001) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(01)00159-0 · Cited by 833
New aspects of natural-killer-cell surveillance and therapy of cancer
Smyth, M. J., Hayakawa, Y., Takeda, K., & Yagita, H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc928 · Cited by 752
Fulda, S., Wick, W., Weller, M., & Debatin, K.-M. (2002) · Nature Medicine · doi:10.1038/nm735 · Cited by 741
Mechanisms of resistance to TRAIL-induced apoptosis in cancer
Zhang, L., & Fang, B. (2005) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700792 · Cited by 702
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
Lawrence, D., Shahrokh, Z., Marsters, S., Achilles, K., Shih, D., Mounho, B., Hillan, K., Totpal, K., DeForge, L., Schow, P., et al. (2001) · Nature Medicine · doi:10.1038/86397 · Cited by 702
Self-citationApoptosis: a basic biological phenomenon with wide‐ranging implications in human disease
FADEEL, B., & ORRENIUS, S. (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2005.01570.x · Cited by 698
A Small Molecule Smac Mimic Potentiates TRAIL- and TNFα-Mediated Cell Death
Li, L., Thomas, R. M., Suzuki, H., De Brabander, J. K., Wang, X., & Harran, P. G. (2004) · Science · doi:10.1126/science.1098231 · Cited by 656
Caspases: pharmacological manipulation of cell death
Lavrik, I. N. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26252 · Cited by 644
CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death
Janssen, E. M., Droin, N. M., Lemmens, E. E., Pinkoski, M. J., Bensinger, S. J., Ehst, B. D., Griffith, T. S., Green, D. R., & Schoenberger, S. P. (2005) · Nature · doi:10.1038/nature03337 · Cited by 619
Wagner, K. W., Punnoose, E. A., Januario, T., Lawrence, D. A., Pitti, R. M., Lancaster, K., Lee, D., von Goetz, M., Yee, S. F., Totpal, K., et al. (2007) · Nature Medicine · doi:10.1038/nm1627 · Cited by 612
Self-citationBedikian, A. Y., Millward, M., Pehamberger, H., Conry, R., Gore, M., Trefzer, U., Pavlick, A. C., DeConti, R., Hersh, E. M., Hersey, P., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.0483 · Cited by 600
Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks
Pommier, Y., Sordet, O., Antony, S., Hayward, R. L., & Kohn, K. W. (2004) · Oncogene · doi:10.1038/sj.onc.1207515 · Cited by 560
Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity
Ichikawa, K., Liu, W., Zhao, L., Wang, Z., Liu, D., Ohtsuka, T., Zhang, H., Mountz, J. D., Koopman, W. J., Kimberly, R. P., et al. (2001) · Nature Medicine · doi:10.1038/91000 · Cited by 543
Inhibition of Fas death signals by FLIPs
Tschopp, J., Irmler, M., & Thome, M. (1998) · Current Opinion in Immunology · doi:10.1016/s0952-7915(98)80223-9 · Cited by 520
LeBlanc, H., Lawrence, D., Varfolomeev, E., Totpal, K., Morlan, J., Schow, P., Fong, S., Schwall, R., Sinicropi, D., & Ashkenazi, A. (2002) · Nature Medicine · doi:10.1038/nm0302-274 · Cited by 507
Self-citationDeath receptors in chemotherapy and cancer
Debatin, K.-M., & Krammer, P. H. (2004) · Oncogene · doi:10.1038/sj.onc.1207558 · Cited by 505
Microtubules, microtubule-interfering agents and apoptosis
Mollinedo, F., & Gajate, C. (2003) · Apoptosis · doi:10.1023/a:1025513106330 · Cited by 477
Waters, J. S., Webb, A., Cunningham, D., Clarke, P. A., Raynaud, F., di Stefano, F., & Cotter, F. E. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.9.1812 · Cited by 454
ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas
Vucic, D., Stennicke, H. R., Pisabarro, M. T., Salvesen, G. S., & Dixit, V. M. (2000) · Current Biology · doi:10.1016/s0960-9822(00)00781-8 · Cited by 414
Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity
Schimmer, A. D., Welsh, K., Pinilla, C., Wang, Z., Krajewska, M., Bonneau, M.-J., Pedersen, I. M., Kitada, S., Scott, F. L., Bailly-Maitre, B., et al. (2004) · Cancer Cell · doi:10.1016/s1535-6108(03)00332-5 · Cited by 411
Mitsiades, C. S., Treon, S. P., Mitsiades, N., Shima, Y., Richardson, P., Schlossman, R., Hideshima, T., & Anderson, K. C. (2001) · Blood · doi:10.1182/blood.v98.3.795 · Cited by 392
Thomas, W. D., & Hersey, P. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.5.2195 · Cited by 326
Ell, K., Sanchez, K., Vourlekis, B., Lee, P.-J., Dwight-Johnson, M., Lagomasino, I., Muderspach, L., & Russell, C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.041 · Cited by 319
Tolcher, A. W., Mita, M., Meropol, N. J., von Mehren, M., Patnaik, A., Padavic, K., Hill, M., Mays, T., McCoy, T., Fox, N. L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8898 · Cited by 314
Kim, Y., Suh, N., Sporn, M., & Reed, J. C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202458200 · Cited by 309
O'Brien, S., Moore, J. O., Boyd, T. E., Larratt, L. M., Skotnicki, A., Koziner, B., Chanan-Khan, A. A., Seymour, J. F., Bociek, R. G., Pavletic, S., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.1191 · Cited by 303
Kelley, R. F., Totpal, K., Lindstrom, S. H., Mathieu, M., Billeci, K., DeForge, L., Pai, R., Hymowitz, S. G., & Ashkenazi, A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m410660200 · Cited by 284
Self-citationApoptosis-based therapies and drug targets
Fischer, U., & Schulze-Osthoff, K. (2005) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401556 · Cited by 282
Role of mitochondrial membrane permeabilization in apoptosis and cancer
Henry-Mowatt, J., Dive, C., Martinou, J.-C., & James, D. (2004) · Oncogene · doi:10.1038/sj.onc.1207534 · Cited by 274
Antiviral response by natural killer cells throughTRAIL gene induction by IFN-α/β
Sato, K., Hida, S., Takayanagi, H., Yokochi, T., Kayagaki, N., Takeda, K., Yagita, H., Okumura, K., Tanaka, N., Taniguchi, T., et al. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(200111)31:11<3138::aid-immu3138>3.0.co;2-b · Cited by 271
Nakata, S., Yoshida, T., Horinaka, M., Shiraishi, T., Wakada, M., & Sakai, T. (2004) · Oncogene · doi:10.1038/sj.onc.1207830 · Cited by 271
Sedger, L. M., Shows, D. M., Blanton, R. A., Peschon, J. J., Goodwin, R. G., Cosman, D. J., & Wiley, S. R. (1999) · PubMed · Cited by 270
Alterations in the apoptotic machinery and their potential role in anticancer drug resistance
Kaufmann, S. H., & Vaux, D. L. (2003) · Oncogene · doi:10.1038/sj.onc.1206945 · Cited by 265
Gliniak, B., & Le, T. (1999) · PubMed · Cited by 261
New Approaches and Therapeutics Targeting Apoptosis in Disease
Fischer, U., & Schulze-Osthoff, K. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.6 · Cited by 257
Ricci, M. S., Kim, S.-H., Ogi, K., Plastaras, J. P., Ling, J., Wang, W., Jin, Z., Liu, Y. Y., Dicker, D. T., Chiao, P. J., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.006 · Cited by 255
Direct Repression of FLIP Expression by c-myc Is a Major Determinant of TRAIL Sensitivity
Ricci, M. S., Jin, Z., Dews, M., Yu, D., Thomas-Tikhonenko, A., Dicker, D. T., & El-Deiry, W. S. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.19.8541-8555.2004 · Cited by 243
The role of the Bcl-2 protein family in cancer
Coultas, L., & Strasser, A. (2003) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00129-3 · Cited by 242
Defining Characteristics of Types I and II Apoptotic Cells in Response to TRAIL
Özören, N., & El-Deiry, W. S. (2002) · Neoplasia · doi:10.1038/sj.neo.7900270 · Cited by 237
Jin, Z., McDonald, E. R., Dicker, D. T., & El-Deiry, W. S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405538200 · Cited by 237
Sedger, L. M., Shows, D. M., Blanton, R. A., Peschon, J. J., Goodwin, R. G., Cosman, D., & Wiley, S. R. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.2.920 · Cited by 232
Kandasamy, K., Srinivasula, S. M., Alnemri, E. S., Thompson, C. B., Korsmeyer, S. J., Bryant, J., & Srivastava, R. K. (2003) · PubMed · Cited by 222
Negative regulation of bcl-2 expression by p53 in hematopoietic cells
Wu, Y.-L., Mehew, J. W., Heckman, C. A., Arcinas, M., & Boxer, L. M. (2001) · Oncogene · doi:10.1038/sj.onc.1204067 · Cited by 221
LaCour, S., Hammann, A., Wotawa, A., Corcos, L., Solary, É., & Dimanche‐Boitrel, M. (2001) · PubMed · Cited by 218
Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma
Trudel, S., Li, Z. H., Rauw, J., Tiedemann, R. E., Wen, X. Y., & Stewart, A. K. (2007) · Blood · doi:10.1182/blood-2006-10-047951 · Cited by 218
Ganten, T. M., Koschny, R., Sykora, J., Schulze-Bergkamen, H., Büchler, P., Haas, T. L., Schader, M. B., Untergasser, A., Stremmel, W., & Walczak, H. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2635 · Cited by 217
Isotype-Dependent Inhibition of Tumor Growth In Vivo by Monoclonal Antibodies to Death Receptor 4
Chuntharapai, A., Dodge, K., Grimmer, K., Schroeder, K., Marsters, S. A., Koeppen, H., Ashkenazi, A., & Kim, K. J. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.8.4891 · Cited by 202
Self-citationNimmanapalli, R., Perkins, C. L., Орландо, М., O'Bryan, E., Nguyen, D. N., & Bhalla, K. N. (2001) · PubMed · Cited by 201
Rowinsky, E. K. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2889 · Cited by 197
Naka, T., Sugamura, K., Hylander, B. L., Widmer, M. B., Rustum, Y. M., & Repasky, E. A. (2002) · PubMed · Cited by 190
Nikrad, M., Johnson, T., Puthalalath, H., Coultas, L., Adams, J., & Kraft, A. S. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0260 · Cited by 180
Drug Insight: cancer therapy strategies based on restoration of endogenous cell death mechanisms
Reed, J. C. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0538 · Cited by 179
Assessing Individual Risk for Prostate Cancer
Nam, R. K., Toi, A., Klotz, L. H., Trachtenberg, J., Jewett, M. A. S., Appu, S., Loblaw, D. A., Sugar, L., Narod, S. A., & Kattan, M. W. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.6450 · Cited by 176
Antiapoptotic BCL-2 is required for maintenance of a model leukemia
Letai, A., Sorcinelli, M. D., Beard, C., & Korsmeyer, S. J. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.07.011 · Cited by 174
Johnson, T. R., Stone, K., Nikrad, M. P., Yeh, T. C., Zong, W., Thompson, C. B., Nesterov, A., & Kraft, A. S. (2003) · Oncogene · doi:10.1038/sj.onc.1206656 · Cited by 173
Apoptosis, cancer and the p53 tumour suppressor gene
Lee, J. M., & Bernstein, A. (1995) · Cancer and Metastasis Reviews · doi:10.1007/bf00665797 · Cited by 169
Guo, F., Nimmanapalli, R., Paranawithana, S., Wittman, S., Griffin, D., Bali, P., O'Bryan, E., Fumero, C., Wang, H. G., & Bhalla, K. (2002) · Blood · doi:10.1182/blood.v99.9.3419 · Cited by 162
Sharp, D. A., Lawrence, D. A., & Ashkenazi, A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413962200 · Cited by 156
Self-citationPharmacological manipulation of Bcl-2 family members to control cell death
Letai, A. G. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26250 · Cited by 155
TRAIL Inhibits Tumor Growth but Is Nontoxic to Human Hepatocytes in Chimeric Mice
Hao, C., Song, J. H., Hsi, B., Lewis, J. T., Song, D. K., Petruk, K. C., Tyrrell, D., & Kneteman, N. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2599 · Cited by 154
Cuello, M. A., Ettenberg, S. A., Nau, M. M., & Lipkowitz, S. (2001) · Gynecologic Oncology · doi:10.1006/gyno.2001.6194 · Cited by 152
Adams, C., Totpal, K., Lawrence, D., Marsters, S., Pitti, R., Yee, S., Ross, S., Deforge, L., Koeppen, H., Sagolla, M., et al. (2008) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402306 · Cited by 148
Self-citationGulbins, E., Jekle, A., Ferlinz, K., Grassmé, H., & Lang, F. J. W. (2000) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.2000.279.4.f605 · Cited by 142
Hyer, M. L., Croxton, R., Krajewska, M., Krajewski, S., Kress, C. L., Lü, M., Suh, N., Sporn, M. B., Cryns, V. L., Zapata, J. M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3319 · Cited by 132
LaCasse, E. C., Cherton-Horvat, G. G., Hewitt, K. E., Jerome, L. J., Morris, S. J., Kandimalla, E. R., Yu, D., Wang, H., Wang, W., Zhang, R., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0608 · Cited by 128
Who Should Be Sent for Genetic Testing in Hereditary Colorectal Cancer Syndromes?
Lynch, H. T., Boland, C. R., Rodríguez-Bigas, M. A., Amos, C. I., Lynch, J. F., & Lynch, P. M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.3119 · Cited by 124
Corazza, N., Jakob, S., Schaer, C., Frese, S., Keogh, A., Stroka, D., Kassahn, D., Torgler, R., Mueller, C., Schneider, P., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27726 · Cited by 123
Mechanisms Governing Expression of the v-FLIP Gene of Kaposi's Sarcoma-Associated Herpesvirus
Grundhoff, A. T., & Ganem, D. (2001) · Journal of Virology · doi:10.1128/jvi.75.4.1857-1863.2001 · Cited by 122
Rosato, R. R., Almenara, J. A., Coe, S., & Grant, S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0598 · Cited by 118
MCL-1 as a Buffer for Proapoptotic BCL-2 Family Members during TRAIL-induced Apoptosis
Meng, X. W., Lee, S. H., Dai, H., Loegering, D. A., Yu, C., Flatten, K. S., Schneider, P. A., Dai, N. T., Kumar, S. K., Smith, B. D., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m706110200 · Cited by 117
Shankar, S., Singh, T. R., & Srivastava, R. K. (2004) · The Prostate · doi:10.1002/pros.20069 · Cited by 115
Ray, S., & Almasan, A. (2003) · PubMed · Cited by 115
Hylander, B. L., Pitoniak, R., Penetrante, R. B., Gibbs, J. F., Oktay, D., Cheng, J., & Repasky, E. A. (2005) · Journal of Translational Medicine · doi:10.1186/1479-5876-3-22 · Cited by 114
Jin, H., Yang, R., Fong, S., Tótpál, K., Lawrence, D. A., Zheng, Z., Ross, J., Koeppen, H., SCHWALL, R. H., & Ashkenazi, A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0408 · Cited by 113
Self-citationDaniel, D., Yang, B., Lawrence, D. A., Tótpál, K., Balter, I., Lee, W. P., Gogineni, A., Cole, M. J., Yee, S. F., Ross, S., et al. (2007) · Blood · doi:10.1182/blood-2007-02-076075 · Cited by 112
Self-citationMitsiades, N., Poulaki, V., Tseleni‐Balafouta, S., Koutras, D. A., & Stamenkovic, I. (2000) · PubMed · Cited by 106
Herbst, R. S., Mendolson, D. S., Ebbinghaus, S., Gordon, M. S., O'Dwyer, P. J., Lieberman, G. S., Ing, J., Kurzrock, R., Novotny, W. F., & Eckhardt, G. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.3013 · Cited by 103
Self-citationSayers, T. J., & Murphy, W. J. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0676-3 · Cited by 102
Grünhagen, D. J., de Wilt, J. H., ten Hagen, T. L. M., & Eggermont, A. M. M. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0426 · Cited by 101
Sinicrope, F. A., Penington, R. C., & Tang, X. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1289 · Cited by 98
Peták, I., Douglas, L., Tillman, D. M., Vernes, R., & Houghton, J. A. (2000) · PubMed · Cited by 95
Genomic Organization and Transcriptional Regulation of Human Apo2/TRAIL Gene
Gong, B., & Almasan, A. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3872 · Cited by 94
Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis
Marini, P., Schmid, A., Jendrossek, V., Faltin, H., Daniel, P. T., Budach, W., & Belka, C. (2005) · BMC Cancer · doi:10.1186/1471-2407-5-5 · Cited by 94
Zhu, L.-J., Somlo, G., Zhou, B.-S., Shao, J., Bedell, V., Slovak, M., Liu, X.-Y., Luo, J.-H., & Yun, Y. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0330 · Cited by 89
El-Zawahry, A. M., McKillop, J. C., & Voelkel‐Johnson, C. (2005) · BMC Cancer · doi:10.1186/1471-2407-5-2 · Cited by 85
Ravi, R. K., Jain, A. J., Schulick, R. D., Pham, V., Prouser, T. S., Allen, H. E., Mayer, E.-G., Yu, H., Pardoll, D. M., Ashkenazi, A., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2488 · Cited by 78
Self-citationMühlethaler‐Mottet, A., Bourloud, K. B., Auderset, K., Joseph, J., & Groß, N. (2004) · Oncogene · doi:10.1038/sj.onc.1207704 · Cited by 74
Sensitization of prostate carcinoma cells to Apo2L/TRAIL by a Bcl-2 family protein inhibitor
Ray, S., Bucur, O., & Almasan, A. (2005) · APOPTOSIS · doi:10.1007/s10495-005-2490-y · Cited by 70
Jahrsdörfer, B., Jox, R. J., Mühlenhoff, L., Tschoep, K., Krug, A., Rothenfußer, S., Meinhardt, G., Emmerich, B., Endres, S., & Hartmann, G. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.72.1.83 · Cited by 69
Sparano, J. A., Moulder, S. L., Kazi, A., Vahdat, L. T., Li, T., Pellegrino, C. M., Munster, P. N., Malafa, M. P., Lee, D., Hoschander, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.9114 · Cited by 68
Yee, L., Fanale, M. A., Dimick, K., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.8078 · Cited by 68
Schimmer, A. D., Thomas, M. P., Hurren, R., Gronda, M., Pellecchia, M., Pond, G. R., Konopleva, M. Y., Gurfinkel, D., Mawji, I. A., Brown, E. R., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1061 · Cited by 67
Trail activity in human ovarian cancer cells
Vignati, S., Codegoni, A. M., Polato, F., & Broggini, M. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00345-8 · Cited by 65
Apoptosis in the treatment of cancer: a promise kept?
Meng, X. W., Lee, S. H., & Kaufmann, S. H. (2006) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2006.10.008 · Cited by 65
Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation
Zhu, H., Guo, W., Zhang, L., Wu, S., Teraishi, F., Davis, J. J., Dong, F., & Fang, B. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.7.1897 · Cited by 61
Synergistic cytotoxicity and apoptosis by Apo-2 ligand and adriamycin against bladder cancer cells.
Mizutani, Y., Yoshida, O., Miki, T., & Bonavida, B. (1999) · PubMed · Cited by 59
Frese, S., Brunner, T., Gugger, M., Uduehi, A. N., & Schmid, R. A. (2002) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1067/mtc.2002.119694 · Cited by 59
Xiang, H., Fox, J. A., Tótpál, K., Aikawa, M., DuPree, K., Sinicropi, D. V., Lowe, J. R., & Escandón, E. (2002) · Oncogene · doi:10.1038/sj.onc.1205449 · Cited by 51
LoRusso, P. M., Hong, D. S., Heath, E. I., Kurzrock, R., Wang, D., Hsu, M. L., Goyal, L., Wiezorek, J. S., Storgard, C. M., & Herbst, R. S. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.3534 · Cited by 50
Self-citationSikic, B. I., Wakelee, H. A., von Mehren, M., Lewis, N. L., Calvert, H., Plummer, E. R., Fox, N. L., Howard, T., Jones, S. F., & Burris, H. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.14006 · Cited by 49
Brooks, A. D., RAMIREZ, T., Toh, U., Onksen, J. L., Elliott, P. J., Murphy, W. J., & Sayers, T. J. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1339.042 · Cited by 38
Chow, L. Q. M., Eckhardt, S. G., Gustafson, D. L., O’Bryant, C. L., Hariharan, S., Diab, S., Fox, N. L., Corey, A. E., Padavic, K., Brown, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.2515 · Cited by 34
Patnaik, A., Wakelee, H. A., Mita, M. M., Fitzgerald, A., Hill, M., Fox, N. L., Howard, T., Ullrich, S. J., Tolcher, A. W., & Sikic, B. I. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.3012 · Cited by 27
Pacey, S., Plummer, R., Attard, G., Bale, C., Calvert, H., Blagden, S. P., Fox, N. L., Corey, A. E., & Bono, J. S. D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.3055 · Cited by 23
Hotte, S. J., Hirte, H. W., Chen, E. X., Le, L., Corey, A. E., Maclean, M., Iacobucci, A. S., Fox, N. L., & Oza, A. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.3052 · Cited by 20
Cited by
Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis
Spencer, S. L., Gaudet, S., Albeck, J. G., Burke, J. M., & Sorger, P. K. (2009) · Nature · doi:10.1038/nature08012 · Cited by 1,021
Molecular targeted therapies in hepatocellular carcinoma†
Llovet, J. M., & Bruix, J. (2008) · Hepatology · doi:10.1002/hep.22506 · Cited by 1,004
Life and death by death receptors
Guicciardi, M. E., & Gores, G. J. (2009) · The FASEB Journal · doi:10.1096/fj.08-111005 · Cited by 690
Latent Bone Metastasis in Breast Cancer Tied to Src-Dependent Survival Signals
Zhang, X. H.-F., Wang, Q., Gerald, W., Hudis, C. A., Norton, L., Smid, M., Foekens, J. A., & Massagué, J. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.05.017 · Cited by 663
Hepatocyte Death: A Clear and Present Danger
Malhi, H., Guicciardi, M. E., & Gores, G. J. (2010) · Physiological Reviews · doi:10.1152/physrev.00061.2009 · Cited by 477
Metadata
- Authors
- Ashkenazi, A., & Herbst, R. S.
- Venue
- Journal of Clinical Investigation
- Published
- 2008-06-02
- Volume
- 118
- Issue
- 6
- Pages
- 1979-1990
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1964304371
- Cited by
- 323
- References
- 127
- FWCI
- 17.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.